{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:25:35Z","timestamp":1786980335957,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To assess the recent real-world changes in the etiologies of liver cirrhosis (LC) in Japan, we conducted a nationwide survey in the annual meeting of the Japan Society of Hepatology (JSH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We investigated the etiologies of LC patients accumulated from 68 participants in 79 institutions (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200948,621). We next assessed changing trends in the etiologies of LC by analyzing cases in which the year of diagnosis was available (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200945,834). We further evaluated the transition in the real number of newly identified LC patients by assessing data from 36 hospitals with complete datasets for 2008\u20132016 (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200918,358).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the overall data, HCV infection (48.2%) was the leading cause of LC in Japan, and HBV infection (11.5%) was the third-most common cause. Regarding the transition in the etiologies of LC, the contribution of viral hepatitis-related LC dropped from 73.4 to 49.7%. Among the non-viral etiologies, alcoholic-related disease (ALD) and nonalcoholic steatohepatitis (NASH)-related LC showed a notable increase (from 13.7 to 24.9% and from 2.0 to 9.1%, respectively). Regarding the real numbers of newly diagnosed patients from 2008 to 2016, the numbers of patients with viral hepatitis-related LC decreased, while the numbers of patients with non-viral LC increased.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HCV has remained the main cause of LC in Japan; however, the contribution of viral hepatitis as an etiology of LC is suggested to have been decreasing. In addition, non-viral LC, such as ALD-related LC and NASH-related LC, is suggested to have increased as etiologies of LC in Japan.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00535-019-01645-y","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T10:03:20Z","timestamp":1574676200000},"page":"353-362","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Transition in the etiology of liver cirrhosis in Japan: a nationwide survey"],"prefix":"10.1007","volume":"55","author":[{"name":"Japan Etiology of Liver Cirrhosis Study Group in the 54th Annual Meeting of JSH","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirayuki","family":"Enomoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Hiasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Hige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Takikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Taniai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohichiroh","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Takaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Ido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Kanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Nishiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,25]]},"reference":[{"key":"1645_CR1","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","volume":"371","author":"D Schuppan","year":"2008","unstructured":"Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838\u201351.","journal-title":"Lancet"},{"key":"1645_CR2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1053\/j.gastro.2018.10.048","volume":"156","author":"JW Ward","year":"2019","unstructured":"Ward JW, Hinman AR. What is needed to eliminate hepatitis B virus and hepatitis C virus as global health threats? Gastroenterology. 2019;156:297\u2013310.","journal-title":"Gastroenterology"},{"key":"1645_CR3","unstructured":"World Health Organization. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/246177\/WHO-HIV-2016.06-eng.pdf;jsessionid=DE9F84140E2A3179E7A7D9476EF93B80?sequence=1. Accessed 5 Aug 2019."},{"key":"1645_CR4","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.29361","volume":"66","author":"HR Rosen","year":"2017","unstructured":"Rosen HR, Ghany MG, Chung RT, et al. NAM 2017 Report: a national plan to eliminate hepatitis B and C in the United States by 2030 and the AASLD\u2019s response. Hepatology. 2017;66:1020\u20132.","journal-title":"Hepatology"},{"key":"1645_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/hepr.12897","volume":"47","author":"N Oza","year":"2017","unstructured":"Oza N, Isoda H, Ono T, Kanto T. Current activities and future directions of comprehensive hepatitis control measures in Japan: the supportive role of the Hepatitis Information Center in building a solid foundation. Hepatol Res. 2017;47:487\u201396.","journal-title":"Hepatol Res."},{"key":"1645_CR6","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1007\/s00535-018-1455-1","volume":"53","author":"K Tsuji","year":"2018","unstructured":"Tsuji K, Kurosaki M, Itakura J, et al. Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Gastroenterol. 2018;53:1142\u201350.","journal-title":"J Gastroenterol."},{"key":"1645_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13410","author":"A Tamori","year":"2019","unstructured":"Tamori A, Inoue K, Kagawa T, et al. Intention-to-treat assessment of glecaprevir + pibrentasvir combination therapy for patients with chronic hepatitis C in the real world. Hepatol Res. 2019. https:\/\/doi.org\/10.1111\/hepr.13410[Epub ahead of print].","journal-title":"Hepatol Res"},{"key":"1645_CR8","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s00535-019-01569-7","volume":"54","author":"A Naganuma","year":"2019","unstructured":"Naganuma A, Chayama K, Notsumata K, et al. Integrated analysis of 8-week glecaprevir\/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. J Gastroenterol. 2019;54:752\u201361.","journal-title":"J Gastroenterol."},{"key":"1645_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/hepr.13282","volume":"49","author":"K Tanaka","year":"2019","unstructured":"Tanaka K, Takahashi H, Hyogo H, et al. Epidemiological survey of hemoglobin A1c and liver fibrosis in a general population with non-alcoholic fatty liver disease. Hepatol Res. 2019;49:296\u2013303.","journal-title":"Hepatol Res."},{"key":"1645_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00535-017-1414-2","volume":"53","author":"M Yoneda","year":"2018","unstructured":"Yoneda M, Imajo K, Takahashi H, et al. Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. J Gastroenterol. 2018;53:181\u201396.","journal-title":"J Gastroenterol."},{"key":"1645_CR11","unstructured":"Ministry of Health, Labour and Welfare. Available at: https:\/\/www.mhlw.go.jp\/toukei\/sippei\/. Accessed 5 Aug 2019."},{"key":"1645_CR12","unstructured":"World Health Organization. ICD-10 Version:2016 https:\/\/icd.who.int\/browse10\/2016\/en. Accessed 5 Aug 2019."},{"key":"1645_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s00535-009-0128-5","volume":"45","author":"K Michitaka","year":"2010","unstructured":"Michitaka K, Nishiguchi S, Aoyagi Y, et al. Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol. 2010;45:86\u201394.","journal-title":"J Gastroenterol."},{"key":"1645_CR14","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/hepr.12056","volume":"43","author":"Y Suzuki","year":"2013","unstructured":"Suzuki Y, Ohtake T, Nishiguchi S, et al. Survey of non-B, non-C liver cirrhosis in Japan. Hepatol Res. 2013;43:1020\u201331.","journal-title":"Hepatol Res."},{"key":"1645_CR15","volume-title":"Clinical guidelines for management of chronic hepatitis and cirrhosis 2016","author":"The Japan Society of Hepatology","year":"2016","unstructured":"The Japan Society of Hepatology. Clinical guidelines for management of chronic hepatitis and cirrhosis 2016. Tokyo: Bun-kodo; 2016."},{"key":"1645_CR16","volume-title":"2nd Edition","author":"Textbook of Hepatology","year":"2016","unstructured":"Textbook of Hepatology. 2nd Edition. Tokyo: Nankodo; 2016."},{"key":"1645_CR17","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00535-018-1532-5","volume":"54","author":"R Tateishi","year":"2019","unstructured":"Tateishi R, Uchino K, Fujiwara N, et al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011\u20132015 update. J Gastroenterol. 2019;54:367\u201376.","journal-title":"J Gastroenterol."},{"key":"1645_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/hepr.12378","volume":"45","author":"Y Osaki","year":"2015","unstructured":"Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: our experience and published work review. Hepatol Res. 2015;45:59\u201374.","journal-title":"Hepatol Res."},{"key":"1645_CR19","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","volume":"17","author":"Z Younossi","year":"2019","unstructured":"Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17:748\u201355.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"1645_CR20","doi-asserted-by":"publisher","first-page":"13546","DOI":"10.3748\/wjg.v20.i37.13546","volume":"20","author":"X Wang","year":"2014","unstructured":"Wang X, Lin SX, Tao J, et al. Study of liver cirrhosis over ten consecutive years in Southern China. World J Gastroenterol. 2014;20:13546\u201355.","journal-title":"World J Gastroenterol."},{"key":"1645_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.5005\/jp-journals-10018-1266","volume":"8","author":"JH Kang","year":"2018","unstructured":"Kang JH, Matsui T. Changing etiology in liver cirrhosis in sapporo Japan. Euroasian J Hepatogastroenterol. 2018;8:77\u201380.","journal-title":"Euroasian J Hepatogastroenterol."},{"issue":"Suppl1","key":"1645_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000048270","volume":"62","author":"H Yoshizawa","year":"2002","unstructured":"Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: Projection to other countries in foreseeable future. Oncology. 2002;62(Suppl1):8\u201317.","journal-title":"Oncology."},{"key":"1645_CR23","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00535-019-01595-5","volume":"54","author":"K Mizuno","year":"2019","unstructured":"Mizuno K, Toyoda H, Yasuda S, et al. The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma. J Gastroenterol. 2019;54:829\u201336.","journal-title":"J Gastroenterol."}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-019-01645-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-019-01645-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-019-01645-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T14:03:40Z","timestamp":1722089020000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-019-01645-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,25]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["1645"],"URL":"https:\/\/doi.org\/10.1007\/s00535-019-01645-y","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,25]]},"assertion":[{"value":"6 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Yoshiyuki Ueno received honoraria from AbbVie and EA-Pharma. Koichi Takaguchi has received honoraria from AbbVie. Masaki Kurosaki received honoraria from Gilead, AbbVie, Bayer, Otsuka and Eisai. Tatsuya Kanto received honoraria from MSD and Gilead. Shuhei Nishiguchi received honoraria from AbbVie and Gilead and research grants from AbbVie, Toray and EA-Pharma. The other authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}